Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy
NCT07502508 on ClinicalTrials.gov · last registry update 2026-06-15
Recruiting now, toward 60 participants. Due to report June 2027, alongside 42 other tracked readouts that quarter. Primary outcome, as filed: To demonstrate that icovamenib 100 mg once daily for 12 weeks is superior to placebo for glycemic control. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- RECRUITING
- Phase
- P2
- Drug
- semaglutideOzempic, Rybelsus, Wegovy
- Sponsor
- Biomea Fusion Inc.
- Sponsor type
- Industry
- Enrollment
- 60
- Started
- 2026-04-30
- Primary completion
- 2027-06 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
To demonstrate that icovamenib 100 mg once daily for 12 weeks is superior to placebo for glycemic control
Conditions studied
Type 2 Diabetes
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.